Pharmaceuticals

Piramal Pharma Solutions recognized by Frost & Sullivan for its End-to-End Integrated Services Across the Entire Drug Development Life Cycle

SANTA CLARA, California, June 18, 2019 /PRNewswire/ -- Based on its recent analysis of the contract development and manufacturing organization market, Frost & Sullivan recognized Piramal Pharma Solutions ('PPS', 'the business') with the 2019 Global Customer Service Leadership Award. Through its 1...

2019-06-18 20:00 454

Seegene Establishes Brazilian Subsidiary

SEOUL, South Korea, June 18, 2019 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered inSouth Korea, announced today the formation of a new subsidiary, Seegene do Brasil Diagnosticos Ltda., inBelo Horizonte, Brazil. Seegene do Brasil Diagnos...

2019-06-18 19:00 266

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings

SUZHOU, China, June 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human ...

2019-06-18 08:00 872

China National Medical Products Administration Approves Sinovant's Clinical Trial Application for Lefamulin

-  Chinese registrational clinical trial for lefamulin to begin in 2H 2019 BEIJING and SHANGHAI, June 14, 2019 /PRNewswire/ -- Sinovant Sciences today announced that its Clinical Trial Application (CTA) for lefamulin has been accepted by the Center for Drug Evaluation at the China National Medica...

2019-06-14 09:00 1668

Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer

* The partnership will leverage Tessa Therapeutics' global operational capabilities and cell therapy platform technologies to target prevalent cancers inChina * The joint venture will be the sole licensee of Tessa Therapeutics' cell therapies for research, development and commercialization in...

2019-06-13 07:15 1132

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

SAN FRANCISCO, June 12, 2019 /PRNewswire/ -- Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The p...

2019-06-12 02:45 1528

Amcor Completes Acquisition of Bemis, Creating the Global Leader in Consumer Packaging

CHICAGO and MELBOURNE, Australia, June 12, 2019 /PRNewswire/ -- Amcor today announces the successful completion of its acquisition of Bemis Company Inc., effective11 June 2019. The combined company will now operate as Amcor plc (Amcor), trading on the New York Stock Exchange under the ticker symb...

2019-06-12 02:26 1481

TauRx Recognized as a Technology Innovation Leader in the Neurodegenerative Disease Management Industry

ABERDEEN, Scotland and SINGAPORE, June 11, 2019 /PRNewswire/ -- TauRx, a leader in neurodegenerative disease research, today announced that it is the recipient of Frost & Sullivan's 2019 Asia Pacific Neurodegenerative Disease Management Technology Innovation Award.

2019-06-11 08:00 1253

Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device

PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Medical ...

2019-06-10 21:00 1485

Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks

Abstracts 54-OR and 55-OR Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance® and Victoza® SAN FRANCISCO, June 8, 2019 /PRNewswire/ -- Findings presented today from two phase 3a clinic...

2019-06-08 23:45 2342

ESPGHAN Researchers Warn: Junk Food Could Be Responsible for the Food Allergy Epidemic

GLASGOW, Scotland, June 8, 2019 /PRNewswire/ -- Experts at the 52nd Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) are today presenting research that shows higher levels of advanced glycation end products (AGEs), found in abundance in ju...

2019-06-08 07:01 3004

Innovent provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO

SUZHOU, China, June 5, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell ly...

2019-06-05 08:00 1978

RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer

Results, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated clinically meaningful response in patients with urothelial carcinoma whose treatment previously failed, a population with high unmet medical need YANTAI, China, June 4, 2019 /PRNewswire/ -- R...

2019-06-04 21:00 2031

Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma

SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of circulating tumor DNA (ctDNA) for predicting response and resistance ...

2019-06-04 08:00 1911

Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma

SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-deve...

2019-06-04 08:00 7845

Innovent Provides Update on Sintilimab in Combination with CAPOX for First-Line Treatment of Patients with Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)

SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of efficacy and safety of sintilimab, the anti-PD-1 antibody...

2019-06-04 08:00 7902

Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations

ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 4, 2019 /PRNewswire/ -- * Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis * N...

2019-06-04 02:16 1837

Frost & Sullivan Publishes Q1 Update on Kadimastem

Continues its plans as expected; Ministry of Health approval for central experiment; financing is required to continue operations at the beginning of 2020; received Orphan Drug Designation from the FDA; target price unchanged. TEL AVIV, Israel, June 3, 2019 /PRNewswire/ -- The TASE analysis proje...

2019-06-03 21:24 1154

Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC) at ASCO, Led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences

SUZHOU, China, June 3, 2019 /PRNewswire/ -- The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC) (ChiCTR-OIC-17013726), led by ProfessorJie He, Dean of the Cancer Hospital of the Chinese Academy of ...

2019-06-03 08:00 10223

Innovent Provides Key Results Update of IBI305 (Biosimilar Product Candidate of Bevacizumab) Compared with Bevacizumab

SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the study results for efficacy and safety of IBI305 (biosimilar of bevacizumab) comp...

2019-06-03 08:00 1509
12345 ... 51